Skip to main content

CPI event to showcase results of AMSCI funded BioStreamline project

CPI event to showcase results of AMSCI funded BioStreamline project
Monday 17 June 2019

CPI event to showcase results of AMSCI funded BioStreamline project

Back to News
Monday 17 June 2019

CPI event to showcase results of AMSCI funded BioStreamline project

AMSCI

CPI, the UK-based technology innovation centre, and part of the High Value Manufacturing Catapult is hosting an event in Darlington, UK on 26 June 2019 to share the results of the £11.2M BioStreamline project. The project aims to optimise the development of novel therapeutics. During the event the project partners will present the project findings and discuss the potential impact on supply chain challenges within the biopharmaceutical industry.


The biopharmaceutical industry requires a more efficient supply chain that can predict issues associated with developing novel biotherapeutics, reduce risk and minimise cost of commercialisation. This has the potential to offer patients access to a wider range of affordable and effective drugs, by limiting the amount of resources wasted.


The BioStreamline project uses state-of-the-art technologies to provide developers with a better understanding of candidate molecules earlier in the development process. The outputs of the project should allow developers to make better informed decisions about which molecules to progress, to address currently unmet medical needs.


BioStreamline is a collaborative project which has brought together cutting-edge expertise from the six partner organisations, across the spectrum of drug discovery and development, with funding from the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI). The six partners were Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI.


John Liddell, Chief Technologist, CPI, said: “We are very excited by the success of the project and feel that a similar approach could be used with other therapeutics, such as viral vectors, which are rapidly emerging as a major therapeutic area. The level of investment that AMSCI has made to this area has provided sufficient breadth of scope to increase understanding of this important aspect of biotherapeutic development, and we are looking forward to presenting the outcomes at the event later this month.”


To register for the event please visit https://www.uk-cpi.com/events/streamlining-the-development-of-next-generation-biotherapeutics.